As a proof of principle study, we revealed that PPP inhibition impeded AKT activation and the proliferation and survival of PTEN null mES cells and human cancer cells, as well as in vivo cancer models, indicating that PTEN null cancer cells may be vulnerable to anti-PPP therapy, even in the presence of a hyperactivated PI3K pathway. Here, AKT1 is linked to cancer.